DRTS

Company Overview — What Does Alpha Tau Medical Ltd. Do?

N/A Alpha Tau Medical Ltd. (DRTS) is classified as a small-cap stock in the Healthcare sector, specifically within the Medical Equipment industry. The company is led by CEO Uzi Sofer and employs approximately 80 people. With a market capitalization of $609M, DRTS is one of the notable companies in the Healthcare sector.

Alpha Tau Medical Ltd. (DRTS) Stock Rating — Reduce (April 2026)

As of April 2026, Alpha Tau Medical Ltd. receives a Reduce rating with a composite score of 45.3/100 and 2 out of 5 stars from the Blank Capital Research quantitative model.DRTS ranks #2,358 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, Alpha Tau Medical Ltd. ranks #286 of 838 stocks, placing it in the upper half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

DRTS Stock Price and 52-Week Range

Alpha Tau Medical Ltd. (DRTS) currently trades at $7.40. The stock gained $0.05 (0.7%) in the most recent trading session. The 52-week high for DRTS is $8.60, which means the stock is currently trading -14.0% from its annual peak. The 52-week low is $2.30, putting the stock 221.7% above its annual trough. Recent trading volume was 126K shares, suggesting relatively thin trading activity.

Is DRTS Overvalued or Undervalued? — Valuation Analysis

Alpha Tau Medical Ltd. (DRTS) carries a value factor score of 31/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The price-to-book ratio stands at 10.03x, versus the sector average of 2.75x.

At current multiples, Alpha Tau Medical Ltd. trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

Alpha Tau Medical Ltd. Profitability — ROE, Margins, and Quality Score

Alpha Tau Medical Ltd. (DRTS) earns a quality factor score of 28/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -202.7%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -147.3% versus the sector average of -33.1%.

Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

DRTS Debt, Balance Sheet, and Financial Health

Alpha Tau Medical Ltd. has a debt-to-equity ratio of 9.0%, compared to the Healthcare sector average of 32.0%. The low leverage indicates a conservative balance sheet with significant financial flexibility. Total debt on the balance sheet is $6M. Cash and equivalents stand at $14M.

DRTS has a beta of 0.80, meaning it is roughly in line with the broader market in terms of price volatility. The stability factor score for Alpha Tau Medical Ltd. is 49/100, reflecting average volatility within the normal range for its sector.

Alpha Tau Medical Ltd. Revenue and Earnings History — Quarterly Trend

In TTM 2026, Alpha Tau Medical Ltd. reported revenue of $0 and earnings per share (EPS) of $-0.45. Net income for the quarter was $-32M. Operating income came in at $-36M.

In FY 2024, Alpha Tau Medical Ltd. reported revenue of $0 and earnings per share (EPS) of $-0.45. Net income for the quarter was $-32M. Operating income came in at $-36M.

In FY 2023, Alpha Tau Medical Ltd. reported revenue of $0 and earnings per share (EPS) of $-0.42. Net income for the quarter was $-29M. Operating income came in at $-36M.

In FY 2022, Alpha Tau Medical Ltd. reported revenue of $0 and earnings per share (EPS) of $-0.53. Net income for the quarter was $-34M. Operating income came in at $-32M.

Over the past 6 quarters, Alpha Tau Medical Ltd. has experienced revenue contraction from $0 to $0. Investors analyzing DRTS stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

DRTS Dividend Yield and Income Analysis

Alpha Tau Medical Ltd. (DRTS) does not currently pay a dividend. This is common among smaller companies in the Medical Equipment industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

DRTS Momentum and Technical Analysis Profile

Alpha Tau Medical Ltd. (DRTS) has a momentum factor score of 75/100, indicating strong price momentum with the stock outperforming the majority of the market over recent periods. Stocks with high momentum scores have historically tended to continue their outperformance in the near term. The investment factor score is 57/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 29/100 signals elevated short interest, which can indicate bearish sentiment among institutional investors.

DRTS vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, Alpha Tau Medical Ltd. (DRTS) ranks #286 out of 838 stocks based on the Blank Capital composite score. This places DRTS in the upper half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing DRTS against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full DRTS vs S&P 500 (SPY) comparison to assess how Alpha Tau Medical Ltd. stacks up against the broader market across all factor dimensions.

DRTS Next Earnings Date

No upcoming earnings date has been announced for Alpha Tau Medical Ltd. (DRTS) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy DRTS? — Investment Thesis Summary

The quantitative profile for Alpha Tau Medical Ltd. suggests caution. The quality score of 28/100 flags below-average profitability. The value score of 31/100 indicates premium valuation. Price momentum is positive at 75/100, suggesting the trend favors buyers.

In summary, Alpha Tau Medical Ltd. (DRTS) earns a Reduce rating with a composite score of 45.3/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on DRTS stock.

Related Resources for DRTS Investors

Explore more research and tools: DRTS vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare DRTS head-to-head with peers: DRTS vs AZN, DRTS vs SLGL, DRTS vs VMD.